Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Tisagenlecleucel

Immune effector cell-associated neurotoxicity syndrome (ICANS), cytokine-release-syndrome (CRS) and bacteraemia: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Goto H, et al. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. International Journal of Clinical Oncology 28 : 816-826, No. 6, Jan 2023. Available from: URL: http://doi.org/10.1007/s10147-023-02334-w Goto H, et al. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. International Journal of Clinical Oncology 28 : 816-826, No. 6, Jan 2023. Available from: URL: http://​doi.​org/​10.​1007/​s10147-023-02334-w
Metadaten
Titel
Tisagenlecleucel
Immune effector cell-associated neurotoxicity syndrome (ICANS), cytokine-release-syndrome (CRS) and bacteraemia: 4 case reports
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-42040-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Levetiracetam